Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling

David P L Sachs, Urbain Säwe, Scott J. Leischow

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Background: To determine the effectiveness of a 16-hour transdermal nicotine patch in assisting smokers to stop smoking, when used in a primary medical practice model. Methods: A single-site, randomized, double-blind, outpatient, parallel-group, placebo-controlled trial consisting of 220 regular, otherwise healthy cigarette smokers. Patients participated in a 12-week patch treatment phase plus a 6-week tapering phase. A standard medical office model of physician intervention, such as could easily be employed by any primary care physician, without need for any special psychological services, training, or skills, was the behavioral intervention. Results: Sustained abstinence, determined at each visit by absolutely no cigarette use, carbon monoxide level of 9 ppm or less, and serum cotinine level of 15 ng/mL or less (after week 18), was significantly greater for those patients receiving the active nicotine patch than for those receiving the placebo patch: the percent of patients not smoking at 6, 12, 18, 26, and 52 weeks was 61% vs 35%, 45% vs 26%, 41% vs 16%, 34% vs 12%, and 25% vs 9%, respectively (P<.001). This 16-hour nicotine patch produced no systemic side effects and minimal skin' irritation. Conclutions: Nicotine replacement therapy via a 16-hour transdermal nicotine patch provided safe and effective treatment for tobacco-dependent patients. One-year sustained nonsmoking rates were nearly three times higher in the active than in the placebo condition, when the patch was used in an easily applicable standard medical practice setting, without the need for psychological interventions. This outcome was as good as or better than results achieved by nicotine patches using behavior modification or group counseling.

Original languageEnglish (US)
Pages (from-to)1881-1890
Number of pages10
JournalArchives of Internal Medicine
Volume153
Issue number16
StatePublished - Aug 23 1993
Externally publishedYes

Fingerprint

Tobacco Use Cessation Products
Counseling
Placebos
Tobacco Products
Smoking
Psychology
Cotinine
Physicians' Offices
Behavior Therapy
Primary Care Physicians
Carbon Monoxide
Nicotine
Tobacco
Outpatients
Therapeutics
Skin
Serum

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. / Sachs, David P L; Säwe, Urbain; Leischow, Scott J.

In: Archives of Internal Medicine, Vol. 153, No. 16, 23.08.1993, p. 1881-1890.

Research output: Contribution to journalArticle

Sachs, David P L ; Säwe, Urbain ; Leischow, Scott J. / Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. In: Archives of Internal Medicine. 1993 ; Vol. 153, No. 16. pp. 1881-1890.
@article{cc23f832de6b42eabbd807cd87b2d9fd,
title = "Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling",
abstract = "Background: To determine the effectiveness of a 16-hour transdermal nicotine patch in assisting smokers to stop smoking, when used in a primary medical practice model. Methods: A single-site, randomized, double-blind, outpatient, parallel-group, placebo-controlled trial consisting of 220 regular, otherwise healthy cigarette smokers. Patients participated in a 12-week patch treatment phase plus a 6-week tapering phase. A standard medical office model of physician intervention, such as could easily be employed by any primary care physician, without need for any special psychological services, training, or skills, was the behavioral intervention. Results: Sustained abstinence, determined at each visit by absolutely no cigarette use, carbon monoxide level of 9 ppm or less, and serum cotinine level of 15 ng/mL or less (after week 18), was significantly greater for those patients receiving the active nicotine patch than for those receiving the placebo patch: the percent of patients not smoking at 6, 12, 18, 26, and 52 weeks was 61{\%} vs 35{\%}, 45{\%} vs 26{\%}, 41{\%} vs 16{\%}, 34{\%} vs 12{\%}, and 25{\%} vs 9{\%}, respectively (P<.001). This 16-hour nicotine patch produced no systemic side effects and minimal skin' irritation. Conclutions: Nicotine replacement therapy via a 16-hour transdermal nicotine patch provided safe and effective treatment for tobacco-dependent patients. One-year sustained nonsmoking rates were nearly three times higher in the active than in the placebo condition, when the patch was used in an easily applicable standard medical practice setting, without the need for psychological interventions. This outcome was as good as or better than results achieved by nicotine patches using behavior modification or group counseling.",
author = "Sachs, {David P L} and Urbain S{\"a}we and Leischow, {Scott J.}",
year = "1993",
month = "8",
day = "23",
language = "English (US)",
volume = "153",
pages = "1881--1890",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "16",

}

TY - JOUR

T1 - Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling

AU - Sachs, David P L

AU - Säwe, Urbain

AU - Leischow, Scott J.

PY - 1993/8/23

Y1 - 1993/8/23

N2 - Background: To determine the effectiveness of a 16-hour transdermal nicotine patch in assisting smokers to stop smoking, when used in a primary medical practice model. Methods: A single-site, randomized, double-blind, outpatient, parallel-group, placebo-controlled trial consisting of 220 regular, otherwise healthy cigarette smokers. Patients participated in a 12-week patch treatment phase plus a 6-week tapering phase. A standard medical office model of physician intervention, such as could easily be employed by any primary care physician, without need for any special psychological services, training, or skills, was the behavioral intervention. Results: Sustained abstinence, determined at each visit by absolutely no cigarette use, carbon monoxide level of 9 ppm or less, and serum cotinine level of 15 ng/mL or less (after week 18), was significantly greater for those patients receiving the active nicotine patch than for those receiving the placebo patch: the percent of patients not smoking at 6, 12, 18, 26, and 52 weeks was 61% vs 35%, 45% vs 26%, 41% vs 16%, 34% vs 12%, and 25% vs 9%, respectively (P<.001). This 16-hour nicotine patch produced no systemic side effects and minimal skin' irritation. Conclutions: Nicotine replacement therapy via a 16-hour transdermal nicotine patch provided safe and effective treatment for tobacco-dependent patients. One-year sustained nonsmoking rates were nearly three times higher in the active than in the placebo condition, when the patch was used in an easily applicable standard medical practice setting, without the need for psychological interventions. This outcome was as good as or better than results achieved by nicotine patches using behavior modification or group counseling.

AB - Background: To determine the effectiveness of a 16-hour transdermal nicotine patch in assisting smokers to stop smoking, when used in a primary medical practice model. Methods: A single-site, randomized, double-blind, outpatient, parallel-group, placebo-controlled trial consisting of 220 regular, otherwise healthy cigarette smokers. Patients participated in a 12-week patch treatment phase plus a 6-week tapering phase. A standard medical office model of physician intervention, such as could easily be employed by any primary care physician, without need for any special psychological services, training, or skills, was the behavioral intervention. Results: Sustained abstinence, determined at each visit by absolutely no cigarette use, carbon monoxide level of 9 ppm or less, and serum cotinine level of 15 ng/mL or less (after week 18), was significantly greater for those patients receiving the active nicotine patch than for those receiving the placebo patch: the percent of patients not smoking at 6, 12, 18, 26, and 52 weeks was 61% vs 35%, 45% vs 26%, 41% vs 16%, 34% vs 12%, and 25% vs 9%, respectively (P<.001). This 16-hour nicotine patch produced no systemic side effects and minimal skin' irritation. Conclutions: Nicotine replacement therapy via a 16-hour transdermal nicotine patch provided safe and effective treatment for tobacco-dependent patients. One-year sustained nonsmoking rates were nearly three times higher in the active than in the placebo condition, when the patch was used in an easily applicable standard medical practice setting, without the need for psychological interventions. This outcome was as good as or better than results achieved by nicotine patches using behavior modification or group counseling.

UR - http://www.scopus.com/inward/record.url?scp=0027380093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027380093&partnerID=8YFLogxK

M3 - Article

C2 - 8110249

AN - SCOPUS:0027380093

VL - 153

SP - 1881

EP - 1890

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 16

ER -